Table 5 Overview of all significant correlations per genetic variant

ABCB1

rs1128503

c.1236C > T

Increased risk anemia grade 3-4

p = 0.023;

Homozygous mutant allele carriers: decreased doctaxel clearance in 92 patients ⁹

OR 1.71, 1.07 – 2.71

ABCC2

rs12762549

g.101620771C > G

Decreased risk anemia grade 3-4

p = 0.004;

Japanese mutant allele carriers: increased risk for severe neutropenia during treatment with docetaxel in 84 patients¹⁹

OR 0.51, 0.33-0.81

rs2073337

c.1668 + 148A > G

Decreased need for colony stimulating factor

p = 0.039;

In vitro evidence: paclitaxel is a substrate of ABCC2²⁴

OR 0.60, 0.37-0.98

ABCC1

rs2074087

c.2284-30 G > C

Increased need for erythropoiesis stimulating agent

p = 0.011;

In vitro evidence: resistance to paclitaxel with ABCC1 overexpression²³

OR 2.09, 1.18-3.68

ABCA1

rs363717

c.1896 A > G

Increased risk anemia grade 3-4

p = 0.002;

Mutant allele carriers: decreased risk to develop thalidomide related neuropathy grade ≥2 in 1495 patients ³⁶

OR 2.08, 1.32-3.27

CYP3A4

rs4986910

c.1331 T > C

Increased risk thrombocytopenia grade 3-4

p = 0.025;

-

OR 4.99, 1.22-20.31

GSTP1

rs1695

c.313A > G

Decreased need for colony stimulating factor

p = 0.017;

Mutant allele carriers: decreased oxaliplatin-related neuropathy in 90 patients³⁰, decreased docetaxel-induced grade 2 neuropathy in 58 patients³¹, decreased risk of hematologic toxicity in 118 patients¹⁵

OR 0.55, 0.33-0.90

Heterozygous mutant allele carriers compared to homozygous wildtype allele carriers: decreased PFS following cisplatin-gemcitabine in 104 patients ³²

ERCC1

rs11615

c.354 T > C

Increased risk anemia grade 3-4

p = 0.031;

Mutant allele carriers: decreased platinum resistance in 60 patients³⁴

OR 1.61, 1.04-2.50

Heterozygous variant allele carriers compared to homozygous wildtype allele carriers: increased risk on severe neutropenia and increased likelihood of overall survival following cisplatin-gemcitabine in 104 patients³²

ERCC2

rs1799793

c.934G > A

Decreased need for colony stimulating factor

p = 0.042;

Heterozygous variant allele carriers compared to homozygous wildtype allele carriers: increased severity of neutropenia following cisplatin-cyclophosphamide in 104 patients³²

OR 0.63, 0.41-0.98

Decreased platinum free interval

p = 0.016,

HR = 0.75, 0.60-0.95